Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A vaccine against pneumonia, the leading cause of child deaths around the world, was rolled out in Kenya Monday and is expected to save hundreds of thousands of lives in coming years.
Pneumococcal disease accounts for 18 percent of child deaths in developing countries, killing more than a million children under the age of five every year, according to the Global Alliance for Vaccines and Immunisation (GAVI).
"Kenya is the first African country to roll-out this pneumococcal conjugate vaccine which has been specially-tailored to meet the needs of children in developing countries," GAVI said in a statement.
GAVI is a public-private body which brings together UN agencies, the World Bank, philanthropists, the vaccine industry and research agencies to improve children's health through immunisation.
It claims to have prevented more than five million deaths since it was created at the World Economic Forum in 2000.
"Routine vaccination is one of the most cost-effective public health investments a government can make and we are counting on our donors to continue their strong backing for our life-saving mission," said Helen Evans, interim CEO of the GAVI Alliance.
GAVI said the launch of its pneumococcal vaccine, now expected to be rolled out in more than 40 countries by 2015, was made possible by an innovative finance mechanism.
Close to three billion dollars from donors allowed the acceleration of production capacity from the two contracted manufacturers, securing the supply of vaccines within a year of their introduction in Europe and the United States and at a fraction of the price charged in rich countries.
"The rapid roll-out of new-generation pneumococcal vaccines shows how innovation and technology can be harnessed, at affordable prices, to save lives in the developing world," World Health Organisation boss Margaret Chan said.
jmm/hv/ga
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments